Next Article in Journal
Synthesis of Novel Diterpenic Peptides via the Ugi Reaction and Their Anticancer Activities
Previous Article in Journal
4-(4-Ethoxyphenyl)-5-(4-methoxyphenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide

Department of Chemistry, Faculty of Science and Analytical Data, Institut Teknologi Sepuluh Nopember, Kampus ITS Sukolilo, Surabaya 60111, Indonesia
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(3), M1706; https://doi.org/10.3390/M1706
Submission received: 3 July 2023 / Revised: 21 July 2023 / Accepted: 23 July 2023 / Published: 1 August 2023
(This article belongs to the Section Organic Synthesis and Biosynthesis)

Abstract

:
N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) was obtained in the form of a colorless solid from the 2-methyl-6-nitrobenzoic anhydride (MNBA)/4-dimethylaminopyridine (DMAP)-catalyzed reaction of 5-bromofuran-2-carboxylic acid and isoniazid in dichloromethane at room temperature with a yield of 83%. The structure of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) was elucidated using 1H NMR, 13C NMR, FTIR, and high-resolution mass spectrometry. Molecular docking screening of the title compound (1) on cyclooxygenase-2 (COX-2) protein (PDB ID: 5IKR) indicated that compound (1) has a good binding affinity, suggesting that further structure optimization and in-depth research can be carried out on compound (1) as a potential COX-2 inhibitor.

1. Introduction

Furan carboxamides are furan amides with various pharmacological activities, including antitumor [1], antifungal [2], antimicrobial [3], anticancer [4], and antidiabetic [5]. Thionyl chloride is commonly used as a coupling agent in the synthesis of amides [6]. However, thionyl chloride has been listed in the Chemical Weapons Convention (CWC) and the Law of the Republic of Indonesia Number 9 of 2008 concerning the use of chemicals and prohibitions on the use of chemicals as chemical weapons [7,8]. Furan carboxamides have been successfully synthesized using hydroxybenzotriazole as a coupling reagent [4], but this material is explosive so its use should be avoided [9]. More environmentally friendly synthesis of furan carboxamides can be carried out using 1,1′-carbonyldiimidazole (CDI) as a coupling agent [10]. However, CDI has low reactivity, especially when compared to similar materials [11]. Alternatively, the synthesis of carboxamides can be carried out by utilizing 2-methyl-6-nitrobenzoic anhydride (MNBA) and 4-dimethylaminopyridine (DMAP) as coupling agent. This has been shown to be advantageous since the reaction can be carried out in one pot at room temperature and the resulting compounds possess high purity and percentage yield [12]. Therefore, this study aims to utilize MNBA/DMAP for the synthesis of furan carboxamide from furoic acid, namely N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1). Molecular docking was carried out to understand the molecular behavior of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) against cyclooxygenase-2 (COX-2) protein.

2. Results and Discussion

2.1. Chemistry

The synthesis of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) was carried out by utilizing the reaction of 5-bromofuran-2-carboxylic acid and isoniazid in the presence of MNBA and DMAP in dichloromethane at room temperature (Scheme 1). The crude product was purified by means of dry-column flash chromatography to obtain pure N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) in the form of a colorless solid with a yield of 83%. The 1H NMR spectrum of the product clearly showed two doublet signals at δ 6.84 and 7.32 ppm indicating two furanyl protons, two doublet signals at δ 7.80 and 8.79 ppm indicating four pyridinyl protons, and two broad singlet signals at δ 10.62 and 10.81 ppm indicating proton signals of the NH groups. The presence of the NH group was confirmed by the IR spectrum, in which a single absorption at a wavenumber of 3168.9 cm−1 can be observed, indicating the presence of a secondary NH group. It was also supported by the 13C NMR spectrum, which exhibited nine signals corresponding to the nine carbon types in the structure of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1). The carbon of the two carbonyl groups gave signals at δ 156.71 and 164.85 ppm; and aromatic carbons signals at δ 114.69, 117.87, 121.84, 126.21, 139.80, 148.41, and 151.05 ppm. The presence of these carbonyl groups was confirmed by the IR spectrum which showed absorption at wavenumbers of 1644.2 and 1682.4 cm−1. The high-resolution mass spectrum further confirmed the reaction product as N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) based on the molecular ion peak at m/z 310.9904 [M + 2H]+ in a positive ionization mode.

2.2. Molecular Docking Study

Molecular docking was carried out to investigate the molecular behavior of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) at the COX-2 protein binding site. Human cyclooxygenase-2 complexed with mefenamic acid (PDB ID: 5IKR) was chosen as a molecular target to examine the interaction of compound (1) with COX-2 protein. Redocking of mefenamic acid, as the native ligand, at the COX-2 binding site resulted in a binding energy of −7.61 kcal/mol and an RMSD value of 0.55 Å (Figure 1).
The docking results showed that the title compound (1) had a binding energy of −7.89 kcal/mol, which was not significantly different from mefenamic acid. Compound (1) exhibited hydrogen bonding, electrostatic interaction, and hydrophobic interaction (Figure 2). The pyridine core of compound (1) generated hydrophobic interactions with Val349 and Leu352 via π–alkyl interactions. One of the carbonyl groups and two NH groups formed hydrogen bonds with Gly526, Met522, and Ala527, respectively. The furan core formed hydrophobic interactions with Val523, Leu352, and Ala527 in the form of π–sigma and π–alkyl interactions. Furthermore, electrostatic interaction was established through π–cation interaction between the furan core and Arg120. Meanwhile, the bromo atom on the furan moiety formed hydrophobic interactions with Tyr385 and Ala527 in the form of π–alkyl and alkyl interactions, respectively.

3. Materials and Methods

The starting materials and reagents used in this study were obtained from Sigma-Aldrich (St. Louis, MO, USA) and Merck (Rahway, NJ, USA) which were used without further purification. Thin layer chromatography was carried out using Merck 0.20 mm precoated silica gel aluminum plates (Kieselgel 60, F254) and was visualized using a 254 nm UV lamp. Dry-column flash chromatography was carried out using Merck silica gel 60H. NMR spectra were obtained in DMSO-d6, using a Jeol JNM-ECS400 spectrometer (400 MHz) (JEOL Ltd., Akishima, Japan). The high-resolution mass spectrum was recorded using the Thermo Scientific TSQ Vantage Triple State Quadrupole spectrometer (Thermo Fisher Scientific, Waltham, MA, USA), while the infrared spectrum was obtained using the Thermo Scientific Nicolet iS10 FTIR spectrometer.

3.1. Synthesis of N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide (1)

The solution of 5-bromofuran-2-carboxylic acid (0.30 g; 1.62 mmol), MNBA (0.39 g; 1.16 mmol), and DMAP (0.26 g; 2.12 mmol) in dichloromethane (10 mL) was stirred at room temperature for 60 min. The solution was added with isoniazid (0.13 g; 0.96 mmol) and was further stirred for 5 days. The reaction was monitored by means of thin layer chromatography with ethyl acetate:methanol (5:1) as the eluent. The reaction product was evaporated under reduced pressure, and the residue was purified by means of dry-column flash chromatography with ethyl acetate: n-hexane (3:1) as the eluent to obtain N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) in the form of a colorless solid (0.25 g, 83% yield); mp: 203 °C; FTIR (KBr, cm−1): 3168.9 (N-H), 1682.4 (C=O amide), 1644.2 (C=O amide); 1H NMR (DMSO-d6, 400 MHz): δ 6.84 (1H, d, J = 3.6 Hz, ArH), 7.32 (1H, d, J = 3.6 Hz, ArH), 7.80 (2H, dd, J = 4.4, 1.6 Hz, ArH), 8.79 (2H, dd, J = 4.4, 1.6 Hz, ArH), 10.62 (1H, bs, NH), 10.81 (1H, bs, NH); 13C NMR (DMSO-d6, 100 MHz): δ 114.69, 117.87, 121.84, 126.21, 139.80, 148.41, 151.05, 156.71, 164.85; HRESIMS m/z (pos): calcd. for C11H10BrN3O3 [M + 2H]+, 310.9906 (79Br) and 312.9885 (81Br); found 310.9904 (79Br) and 312.9886 (81Br) (Supplementary Materials).

3.2. Molecular Docking Study

The crystal structure of the COX-2 protein was obtained from the Protein Data Bank (PDB ID: 5IKR) and prepared using MGLTools 1.5.6 [13]. The 3D structure of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) was generated using the MarvinSketch tool [14]. The location of the receptor binding site was set using a grid box placed at the position of the native ligand (mefenamic acid) with a centering of x: 38.042; y: 2.131; z: 61.280, xyz dimensions of 30 × 30 × 30, and a spacing of 0.375 Å. The 200 iterations of the Lamarckian genetic algorithm were performed on the Autodock4.2 program in order to obtain the best binding pose of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) at the binding site of COX-2 protein [15]. The complex formed between compound (1) and COX-2 was analyzed using Biovia Discovery Studio 2020 [16].

4. Conclusions

N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) was successfully synthesized from the reaction of 5-bromofuran-2-carboxylic acid and isoniazid in the presence of MNBA and DMAP with a yield of 83%. Molecular docking showed that N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1) interacted with residues of the COX-2 protein through several interactions, namely hydrogen bonding, electrostatic interaction, and hydrophobic interaction. The resulting compound had a good binding affinity with a value of −7.89 kcal/mol. Isonicotinohydrazide has the potential to serve as a lead structure in the development of a COX-2 inhibitor.

Supplementary Materials

The following supporting information can be downloaded online: Figure S1: IR spectrum of the title compound (1); Figure S2: 1H NMR spectrum of the title compound (1); Figure S3: 13C NMR spectrum of the title compound (1); Figure S4: Mass spectrum of the title compound (1).

Author Contributions

Conceptualization, M.S.; methodology, M.S.; software, N.P.A.; validation, E.S. and E.Y.R.; formal analysis, E.Y.R.; investigation, E.Y.R.; resources, M.S.; data curation, L.A.; writing—original draft preparation, E.Y.R.; writing—review and editing, M.S. and N.P.A.; visualization, N.P.A.; supervision, M.S.; project administration, M.S.; funding acquisition, M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Institut Teknologi Sepuluh Nopember (Penelitian Keilmuan ITS grant number 1690/PKS/ITS/2023).

Data Availability Statement

The data presented in this study are available in the Supplementary Materials.

Acknowledgments

The authors acknowledge Institut Teknologi Sepuluh Nopember for funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Tikhomirov, A.S.; Lin, C.Y.; Volodina, Y.L.; Dezhenkova, L.G.; Tatarskiy, V.V.; Schols, D.; Shtil, A.A.; Kaur, P.; Chueh, P.J.; Shchekotikhin, A.E. New Antitumor Anthra[2,3-b]Furan-3-Carboxamides: Synthesis and Structure-Activity Relationship. Eur. J. Med. Chem. 2018, 148, 128–139. [Google Scholar] [CrossRef]
  2. Yang, Z.; Sun, Y.; Liu, Q.; Li, A.; Wang, W.; Gu, W. Design, Synthesis, and Antifungal Activity of Novel Thiophene/Furan-1,3,4-Oxadiazole Carboxamides as Potent Succinate Dehydrogenase Inhibitors. J. Agric. Food Chem. 2021, 69, 13373–13385. [Google Scholar] [CrossRef] [PubMed]
  3. Zanatta, N.; Alves, S.H.; Coelho, H.S.; Borchhardt, D.M.; Machado, P.; Flores, K.M.; da Silva, F.M.; Spader, T.B.; Santurio, J.M.; Bonacorso, H.G.; et al. Synthesis, Antimicrobial Activity, and QSAR Studies of Furan-3-Carboxamides. Bioorg. Med. Chem. 2007, 15, 1947–1958. [Google Scholar] [CrossRef]
  4. Zhan, W.; Xu, L.; Dong, X.; Dong, J.; Yi, X.; Ma, X.; Qiu, N.; Li, J.; Yang, B.; Zhou, Y.; et al. Design, Synthesis and Biological Evaluation of Pyrazol-Furan Carboxamide Analogues as Novel Akt Kinase Inhibitors. Eur. J. Med. Chem. 2016, 117, 47–58. [Google Scholar] [CrossRef]
  5. He, M.; Li, Y.-J.; Shao, J.; Li, Y.-S.; Cui, Z.-N. Synthesis and Biological Evaluation of 2,5-Disubstituted Furan Derivatives Containing 1,3-Thiazole Moiety as Potential α-Glucosidase Inhibitors. Bioorg. Med. Chem. Lett. 2023, 83, 129173. [Google Scholar] [CrossRef]
  6. Monier, M.; El-Mekabaty, A.; Elattar, K.M. Five-Membered Ring Systems with One Heteroatom: Synthetic Routes, Chemical Reactivity, and Biological Properties of Furan-Carboxamide Analogues. Synth. Commun. 2018, 48, 839–875. [Google Scholar] [CrossRef]
  7. Narasimhan, B.; Belsare, D.; Pharande, D.; Mourya, V.; Dhake, A. Esters, Amides and Substituted Derivatives of Cinnamic Acid: Synthesis, Antimicrobial Activity and QSAR Investigations. Eur. J. Med. Chem. 2004, 39, 827–834. [Google Scholar] [CrossRef] [PubMed]
  8. Zhang, M.; Lu, X.; Zhang, H.J.; Li, N.; Xiao, Y.; Zhu, H.L.; Ye, Y.H. Synthesis, Structure, and Biological Assay of Cinnamic Amides as Potential EGFR Kinase Inhibitors. Med. Chem. Res. 2013, 22, 986–994. [Google Scholar] [CrossRef]
  9. Dunetz, J.R.; Magano, J.; Weisenburger, G.A. Large-Scale Applications of Amide Coupling Reagents for the Synthesis of Pharmaceuticals. Org. Process Res. Dev. 2016, 20, 140–177. [Google Scholar] [CrossRef]
  10. Shwetha, B.; Sudhanva, M.S.; Jagadeesha, G.S.; Thimmegowda, N.R.; Hamse, V.K.; Sridhar, B.T.; Thimmaiah, K.N.; Ananda Kumar, C.S.; Shobith, R.; Rangappa, K.S. Furan-2-Carboxamide Derivative, a Novel Microtubule Stabilizing Agent Induces Mitotic Arrest and Potentiates Apoptosis in Cancer Cells. Bioorg. Chem. 2021, 108, 104586. [Google Scholar] [CrossRef] [PubMed]
  11. Métro, T.X.; Martinez, J.; Lamaty, F. 1,1′-Carbonyldiimidazole and Mechanochemistry: A Shining Green Combination. ACS Sustain. Chem. Eng. 2017, 5, 9599–9602. [Google Scholar] [CrossRef]
  12. Shiina, I.; Kawakita, Y.I. The Effective Use of Substituted Benzoic Anhydrides for the Synthesis of Carboxamides. Tetrahedron 2004, 60, 4729–4733. [Google Scholar] [CrossRef]
  13. Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Iyashiro, J.M.; Penning, T.D.; Seibert, K.; et al. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-Inflammatory Agents. Nature 1996, 384, 644–648. [Google Scholar] [CrossRef] [PubMed]
  14. Aijijiyah, N.P.; Wati, F.A.; Rahayu, R.; Srilistiani, A.; Mahzumi, F.; Aulia, T.; Santoso, L.; Pamela, E.; Ramadhani, E.Y.; Ilfahmi, Y.A.; et al. Synthesis, α-Glucosidase Inhibitory Activity, and Molecular Docking of Cinnamamides. Med. Chem. Res. 2023, 32, 723–735. [Google Scholar] [CrossRef]
  15. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Santoso, M.; Pamela, E.; Ramadhani, E.Y.; Ilfahmi, Y.A.; Aijijiyah, N.P.; Purnomo, A.S.; Putra, S.R. 4-Methoxyphenethyl (E)-3-(o-Tolyl)acrylate. Molbank 2022, 2022, M1519. [Google Scholar] [CrossRef]
Scheme 1. Synthesis of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1).
Scheme 1. Synthesis of N′-(5-bromofuran-2-carbonyl)isonicotinohydrazide (1).
Molbank 2023 m1706 sch001
Figure 1. Redocked mefenamic acid (green) was superimposed onto the crystallographic mefenamic acid (red) in the binding site of the COX-2 protein (PDB ID: 5IKR).
Figure 1. Redocked mefenamic acid (green) was superimposed onto the crystallographic mefenamic acid (red) in the binding site of the COX-2 protein (PDB ID: 5IKR).
Molbank 2023 m1706 g001
Figure 2. Binding pose and interaction of the compound (1) in the binding site of the COX-2 protein (PDB ID: 5IKR).
Figure 2. Binding pose and interaction of the compound (1) in the binding site of the COX-2 protein (PDB ID: 5IKR).
Molbank 2023 m1706 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ramadhani, E.Y.; Aijijiyah, N.P.; Santoso, E.; Atmaja, L.; Santoso, M. N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide. Molbank 2023, 2023, M1706. https://doi.org/10.3390/M1706

AMA Style

Ramadhani EY, Aijijiyah NP, Santoso E, Atmaja L, Santoso M. N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide. Molbank. 2023; 2023(3):M1706. https://doi.org/10.3390/M1706

Chicago/Turabian Style

Ramadhani, Ersya Yanu, Nur Pasca Aijijiyah, Eko Santoso, Lukman Atmaja, and Mardi Santoso. 2023. "N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide" Molbank 2023, no. 3: M1706. https://doi.org/10.3390/M1706

APA Style

Ramadhani, E. Y., Aijijiyah, N. P., Santoso, E., Atmaja, L., & Santoso, M. (2023). N′-(5-Bromofuran-2-carbonyl)isonicotinohydrazide. Molbank, 2023(3), M1706. https://doi.org/10.3390/M1706

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop